Racial differences in atrial fibrillation-related cardiovascular disease and mortality the Atherosclerosis Risk in Communities (ARIC) study

JAMA Cardiology

Volumn 1, Issue 4, 2016, Pages 433-441

  Magnani, Jared W ^a,b   Norby, Faye L ^c   Agarwal, Sunil K ^d   Soliman, Elsayed Z ^e   Chen, Lin Y ^f   Loehr, Laura R ^g   Alonso, Alvaro ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g The University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLACK PERSON; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUCASIAN; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; RACE DIFFERENCE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPLICATION; ETHNOLOGY; MORTALITY; PROSPECTIVE STUDY; RISK;

AFRICAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK;

EID: 85012973860     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.1025     Document Type: Article

References (46)

1. Magnani JW, RienstraM, Lin H, et al. Atrial fibrillation: Current knowledge and future directions in epidemiology and genomics. Circulation. 2011; 124(18):1982-1993.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370-2375.
3. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes. 2012;5 (1):85-93.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22(8):983-988.
5. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation. 2003;107 (23):2920-2925.
6. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98(10):946-952.
7. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305(20):2080-2087.
8. Thomas KL, Piccini JP, Liang L, et al; Get With the Guidelines Steering Committee and Hospitals. Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc. 2013;2(5): E000200.
9. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation. 2013;128(23): 2470-2477.
10. Shen AY, Contreras R, Sobnosky S, et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults: A cross-sectional study. J Natl Med Assoc. 2010;102(10):906-913.
11. Birman-Deych E, RadfordMJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37 (4):1070-1074.
12. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158 (1):111-117.
13. Lipworth L, Okafor H, Mumma MT, et al. Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study. Am J Cardiol. 2012;110(11):1637-1642.
14. Rodriguez CJ, Soliman EZ, Alonso A, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: The Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015;25(2):71-76, 76.e1.
15. Yancy CW, Benjamin EJ, Fabunmi RP, Bonow RO. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: Executive summary. Circulation. 2005;111(10):1339-1349.
16. Amponsah MK, Benjamin EJ, Magnani JW. Atrial fibrillation and race: A contemporary review. Curr Cardiovasc Risk Rep. 2013;7(5).
17. Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, ChenW. Racial/Ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39(10): 2736-2743.
18. Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: The REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010;41(4):581-587.
19. Bhave PD, Lu X, Girotra S, Kamel H, Vaughan SarrazinMS. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015;12(7):1406-1412.
20. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol. 1989;129(4):687-702.
21. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;159 (5):850-856.
22. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):141-147.
23. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30(4):736-743.
24. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101(7): 1016-1022.
25. Soliman EZ, Lopez F, O'NealWT, et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevationmyocardial infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015;131(21):1843-1850.
26. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study:methods and initial two years' experience. J Clin Epidemiol. 1996;49(2):223-233.
27. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47-55.
28. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
29. Chronic DiseaseWarehouse. Chronic Conditions. https://www.ccwdata.org/web/guest /condition-categories. Accessed February 18, 2016.
30. Taylor AL. Racial differences and racial disparities: The distinction matters. Circulation. 2015;131(10):848-850.
31. Schwamm LH, Reeves MJ, PanW, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation. 2010;121(13):1492-1501.
32. Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd-Jones DM. Racial differences in risks for first cardiovascular events and noncardiovascular death: The Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, and the Multi-Ethnic Study of Atherosclerosis. Circulation. 2012;126(1):50-59.
33. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2015 update: A report from the American Heart Association. Circulation. 2015;131 (4):e29-e322.
34. Ibrahim SA, Kwoh CK, Harper DL, Baker DW. Racial differences in the utilization of oral anticoagulant therapy in heart failure: A study of elderly hospitalized patients. J Gen Intern Med. 2000;15(2):134-137.
35. VanWagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm. 2015;12(1): E5-e29.
36. January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patientswith atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64 (21):e1-e76.
37. LewisWR, Piccini JP, TurakhiaMP, et al. Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2014;7(5):770-777.
38. Bush D, Martin LW, Leman R, Chandler M, Haywood LJ; NHLBI AFFIRM Investigators. Atrial fibrillation among African Americans, Hispanics and Caucasians: Clinical features and outcomes from the AFFIRM trial. J Natl Med Assoc. 2006;98(3):330-339.
39. Reiffel JA, Kowey PR, Myerburg R, et al; AFFECTS Scientific Advisory Committee and Investigators. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry).Am J Cardiol. 2010;105(8):1122-1129.
40. Le Heuzey JY, Breithardt G, Camm J, et al. The RecordAF study: Design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation.Am J Cardiol. 2010;105(5):687-693.
41. RienstraM, Hagens VE, Van Veldhuisen DJ, et al; RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. Clinical characteristics of persistent lone atrial fibrillation in the RACE study.Am J Cardiol. 2004;94(12):1486-1490.
42. Groenveld HF, Crijns HJ, Van den BergMP, et al; RACE II Investigators. The effect of rate control on quality of life in patients with permanent atrial fibrillation: Data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58(17):1795-1803.
43. Van Gelder IC, Groenveld HF, Crijns HJ, et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373.
44. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
45. Akinboboye O. Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: Is there a treatment disparity?. J Multidiscip Healthc. 2015;8:217-228.
46. Prineas RJ, Soliman EZ, Howard G, et al. The sensitivity of the method used to detect atrial fibrillation in population studies affects group-specific prevalence estimates: Ethnic and regional distribution of atrial fibrillation in the REGARDS study. J Epidemiol. 2009;19(4):177-181.